SCHEDULE 13G/A: BlackRock Amends Stake in Arrowhead Pharmaceuticals, Disclosing 13.8% Beneficial Ownership

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 3 to Schedule 13G, reporting its beneficial ownership in ARROWHEAD PHARMACEUTICALS INC.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 19,012,855 shares of Arrowhead Pharmaceuticals Inc. Common Stock.
• This ownership represents 13.8% of the total outstanding class of securities.
• BlackRock, Inc. holds sole voting power over 18,877,477 shares and sole dispositive power over 19,012,855 shares.
• No shared voting or dispositive power is reported by BlackRock, Inc.
• iShares Core S&P Small-Cap ETF, an entity associated with BlackRock, Inc., is noted to have an interest exceeding five percent of the total outstanding common stock of Arrowhead Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership, which is generally neutral in sentiment unless there's a significant, unexpected change in ownership or intent. This amendment reflects ongoing reporting.

Positives

• BlackRock, a major institutional investor, maintains a significant 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc., indicating continued investment interest.

Negatives

• The Schedule 13G filing itself does not contain information regarding the operational or financial performance of Arrowhead Pharmaceuticals Inc. that would indicate negatives.

Risks

• The filing does not detail specific risks related to Arrowhead Pharmaceuticals Inc.'s operations or financial health, as its primary purpose is to disclose beneficial ownership.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing is a routine disclosure of a significant institutional ownership stake in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment firm's portfolio allocation within the sector.

Stakeholder Impact

• Shareholders: Provides transparency on a major institutional investor's stake, which can influence market perception and confidence.

Next Steps

• Ongoing compliance with SEC reporting requirements for beneficial ownership by BlackRock, Inc.

Key Dates

Keywords

BlackRock, Arrowhead Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Pharmaceuticals